|
1
|
Benson DM Jr, Bakan CE, Mishra A,
Hofmeister CC, Efebera Y, Becknell B, Baiocchi RA, Zhang J, Yu J,
Smith MK, et al: The PD-1/PD-L1 axis modulates the natural killer
cell versus multiple myeloma effect: A therapeutic target for
CT-011, a novel monoclonal anti-PD-1 antibody. Blood.
116:2286–2294. 2010. View Article : Google Scholar
|
|
2
|
Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ,
Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, et al:
Safety and activity of anti-PD-L1 antibody in patients with
advanced cancer. N Engl J Med. 366:2455–2465. 2012. View Article : Google Scholar
|
|
3
|
Tykodi SS, Brahmer JR, Hwu WJ, Chow LQ,
Topalian SL, Hwu P, Odunsi K, Camacho LH, Kauh JS, Pitot HC, et al:
PD-1/PD-L1 pathway as a target for cancer immunotherapy: Safety and
clinical activity of BMS-936559, an anti-PD-L1 antibody, in
patients with solid tumors. J Clin Oncol. 30:25102012.
|
|
4
|
Chen DS, Irving BA and Hodi FS: Molecular
pathways: Next-generation immunotherapy - inhibiting programmed
death-ligand 1 and programmed death-1. Clin Cancer Res.
18:6580–6587. 2012. View Article : Google Scholar
|
|
5
|
Horn L, Herbst RS, Spigel D, Gettinger SN,
Gordon MS, Hollebecque and Kowanetz M: An analysis of the
relationship of clinical activity to baseline EGFR status, PD-L1
expression and prior treatment history in patients with non-small
cell lung cancer (NSCLC) following PD-L1 blockade with MPDL3280A
(anti-PDL1). J Thorac Oncol. 8:S3642013.
|
|
6
|
Powles T, Eder JP, Fine GD, Braiteh FS,
Loriot Y, Cruz C, Bellmunt J, Burris HA, Petrylak DP, Teng SL, et
al: MPDL3280A (anti-PD-L1) treatment leads to clinical activity in
metastatic bladder cancer. Nature. 515:558–562. 2014. View Article : Google Scholar
|
|
7
|
Creelan BC: Update on immune checkpoint
inhibitors in lung cancer. Cancer Contr. 21:80–89. 2014. View Article : Google Scholar
|
|
8
|
Stewart R, Morrow M, Hammond SA, Mulgrew
K, Marcus D, Poon E, Watkins A, Mullins S, Chodorge M, Andrews J,
et al: Identification and characterization of MEDI4736, an
antagonistic anti-PD-L1 monoclonal antibody. Cancer Immunol Res.
3:1052–1062. 2015. View Article : Google Scholar
|
|
9
|
Massard C, Gordon MS, Sharma S, Rafii S,
Wainberg ZA, Luke J, Curiel TJ, Colon-Otero G, Hamid O, Sanborn RE,
et al: Safety and efficacy of durvalumab (MEDI4736), an
anti-programmed cell death ligand-1 immune checkpoint inhibitor, in
patients with advanced urothelial bladder cancer. J Clin Oncol.
34:3119–3125. 2016. View Article : Google Scholar
|
|
10
|
West EE, Jin HT, Rasheed AU,
Penaloza-Macmaster P, Ha SJ, Tan WG, Youngblood B, Freeman GJ,
Smith KA and Ahmed R: PD-L1 blockade synergizes with IL-2 therapy
in reinvigorating exhausted T cells. J Clin Invest. 123:2604–2615.
2013. View
Article : Google Scholar
|
|
11
|
Strome SE, Dong H, Tamura H, Voss SG,
Flies DB, Tamada K, Salomao D, Cheville J, Hirano F, Lin W, et al:
B7-H1 blockade augments adoptive T-cell immunotherapy for squamous
cell carcinoma. Cancer Res. 63:6501–6505. 2003.
|
|
12
|
Hamanishi J, Mandai M, Ikeda T, Minami M,
Kawaguchi A, Murayama T, Kanai M, Mori Y, Matsumoto S, Chikuma S,
et al: Efficacy and safety of anti-PD-1 antibody (nivolumab:
BMS-936558, ONO-4538) in patients with platinum-resistant ovarian
cancer. J Clin Oncol. 32:55112014.
|
|
13
|
Hodi FS, Sznol M, Kluger HM, Mcdermott DF,
Carvajal RD, Lawrence DP, Topalian SL, Atkins MB, Powderly JD,
Sharfman WH, et al: Long-term survival of ipilimumab-naive patients
(pts) with advanced melanoma (mel) treated with nivolumab
(anti-pd-1, bms-936558, ono-4538) in a phase I trial. J Clin Oncol.
25:374–393. 2014.
|
|
14
|
Dong H, Strome SE, Salomao DR, Tamura H,
Hirano F, Flies DB, Roche PC, Lu J, Zhu G, Tamada K, et al:
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential
mechanism of immune evasion. Nat Med. 8:793–800. 2002. View Article : Google Scholar
|
|
15
|
Woo SR, Turnis ME, Goldberg MV, Bankoti J,
Selby M, Nirschl CJ, Bettini ML, Gravano DM, Vogel P, Liu CL, et
al: Immune inhibitory molecules LAG-3 and PD-1 synergistically
regulate T-cell function to promote tumoral immune escape. Cancer
Res. 72:917–927. 2012. View Article : Google Scholar
|
|
16
|
Mangsbo SM, Sandin LC, Anger K, Korman AJ,
Loskog A and Tötterman TH: Enhanced tumor eradication by combining
CTLA-4 or PD-1 blockade with CpG therapy. J Immunother. 33:225–235.
2010. View Article : Google Scholar
|
|
17
|
Steidl C, Shah SP, Woolcock BW, Rui L,
Kawahara M, Farinha P, Johnson NA, Zhao Y, Telenius A, Neriah SB,
et al: MHC class II transactivator CIITA is a recurrent gene fusion
partner in lymphoid cancers. Nature. 471:377–381. 2011. View Article : Google Scholar
|
|
18
|
Francisco LM, Salinas VH, Brown KE,
Vanguri VK, Freeman GJ, Kuchroo VK and Sharpe AH: PD-L1 regulates
the development, maintenance, and function of induced regulatory T
cells. J Exp Med. 206:3015–3029. 2009. View Article : Google Scholar
|
|
19
|
Inman BA, Sebo TJ, Frigola X, Dong H,
Bergstralh EJ, Frank I, Fradet Y, Lacombe L and Kwon ED: PD-L1
(B7-H1) expression by urothelial carcinoma of the bladder and
BCG-induced granulomata: Associations with localized stage
progression. Cancer. 109:1499–1505. 2007. View Article : Google Scholar
|
|
20
|
Ahmadzadeh M, Johnson LA, Heemskerk B,
Wunderlich JR, Dudley ME, White DE and Rosenberg SA: Tumor
antigen-specific CD8 T cells infiltrating the tumor express high
levels of PD-1 and are functionally impaired. Blood. 114:1537–1544.
2009. View Article : Google Scholar
|
|
21
|
Hirano F, Kaneko K, Tamura H, Dong H, Wang
S, Ichikawa M, Rietz C, Flies DB, Lau JS, Zhu G, et al: Blockade of
B7-H1 and PD-1 by monoclonal antibodies potentiates cancer
therapeutic immunity. Cancer Res. 65:1089–1096. 2005.
|
|
22
|
Okudaira K, Hokari R, Tsuzuki Y, Okada Y,
Komoto S, Watanabe C, Kurihara C, Kawaguchi A, Nagao S, Azuma M, et
al: Blockade of B7-H1 or B7-DC induces an anti-tumor effect in a
mouse pancreatic cancer model. Int J Oncol. 35:741–749. 2009.
|
|
23
|
Wong RM, Scotland RR, Lau RL, Wang C,
Korman AJ, Kast WM and Weber JS: Programmed death-1 blockade
enhances expansion and functional capacity of human melanoma
antigen-specific CTLs. Int Immunol. 19:1223–1234. 2007. View Article : Google Scholar
|
|
24
|
Curiel TJ, Wei S, Dong H, Alvarez X, Cheng
P, Mottram P, Krzysiek R, Knutson KL, Daniel B, Zimmermann MC, et
al: Blockade of B7-H1 improves myeloid dendritic cell-mediated
antitumor immunity. Nat Med. 9:562–567. 2003. View Article : Google Scholar
|
|
25
|
Zhang Y, Huang S, Gong D, Qin Y and Shen
Q: Programmed death-1 upregulation is correlated with dysfunction
of tumor-infiltrating CD8+ T lymphocytes in human
non-small cell lung cancer. Cell Mol Immunol. 7:389–395. 2010.
View Article : Google Scholar
|
|
26
|
Rupa P, Nakamura S, Katayama S and Mine Y:
Attenuation of allergic immune response phenotype by mannosylated
egg white in orally induced allergy in BALB/c mice. J Agric Food
Chem. 62:9479–9487. 2014. View Article : Google Scholar
|
|
27
|
Boyoglu-Barnum S, Chirkova T, Todd SO,
Barnum TR, Gaston KA, Jorquera P, Haynes LM, Tripp RA, Moore ML and
Anderson LJ: Prophylaxis with a respiratory syncytial virus (RSV)
anti-G protein monoclonal antibody shifts the adaptive immune
response to RSV rA2-line19F infection from Th2 to Th1 in BALB/c
mice. J Virol. 88:10569–10583. 2014. View Article : Google Scholar
|
|
28
|
Pali-Schöll I, Szöllösi H, Starkl P,
Scheicher B, Stremnitzer C, Hofmeister A, Roth-Walter F, Lukschal
A, Diesner SC, Zimmer A, et al: Protamine nanoparticles with
CpG-oligodeoxynucleotide prevent an allergen-induced Th2-response
in BALB/c mice. Eur J Pharm Biopharm. 85(3 Pt A): 656–664. 2013.
View Article : Google Scholar
|
|
29
|
Webster WS, Thompson RH, Harris KJ,
Frigola X, Kuntz S, Inman BA and Dong H: Targeting molecular and
cellular inhibitory mechanisms for improvement of antitumor memory
responses reactivated by tumor cell vaccine. J Immunol.
179:2860–2869. 2007. View Article : Google Scholar
|
|
30
|
Zhou Q, Xiao H, Liu Y, Peng Y, Hong Y,
Yagita H, Chandler P, Munn DH, Mellor A, Fu N, et al: Blockade of
programmed death-1 pathway rescues the effector function of
tumor-infiltrating T cells and enhances the antitumor efficacy of
lentivector immunization. J Immunol. 185:5082–5092. 2010.
View Article : Google Scholar
|
|
31
|
Marusich MF: Efficient hybridoma
production using previously frozen splenocytes. J Immunol Methods.
114:155–159. 1988. View Article : Google Scholar
|
|
32
|
Campbell AM: Monoclonal Antibody
Technology. Elsevier Science Publishers; Amsterdam: pp. 2641984
|
|
33
|
Laemmli UK: Cleavage of structural
proteins during the assembly of the head of bacteriophage T4.
Nature. 227:680–685. 1970. View Article : Google Scholar
|
|
34
|
Detre S, Saclani Jotti G and Dowsett M: A
‘quickscore’ method for immunohistochemical semiquantitation:
Validation for oestrogen receptor in breast carcinomas. J Clin
Pathol. 48:876–878. 1995. View Article : Google Scholar
|
|
35
|
Wang BJ, Bao JJ, Wang JZ, Wang Y, Jiang M,
Xing MY, Zhang WG, Qi JY, Roggendorf M, Lu MJ, et al:
Immunostaining of PD-1/PD-Ls in liver tissues of patients with
hepatitis and hepatocellular carcinoma. World J Gastroenterol.
17:3322–3329. 2011. View Article : Google Scholar
|
|
36
|
Shi F, Shi M, Zeng Z, Qi RZ, Liu ZW, Zhang
JY, Yang YP, Tien P and Wang FS: PD-1 and PD-L1 upregulation
promotes CD8(+) T-cell apoptosis and postoperative recurrence in
hepatocellular carcinoma patients. Int J Cancer. 128:887–896. 2011.
View Article : Google Scholar
|
|
37
|
Keir ME, Butte MJ, Freeman GJ and Sharpe
AH: PD-1 and its ligands in tolerance and immunity. Annu Rev
Immunol. 26:677–704. 2008. View Article : Google Scholar
|
|
38
|
Yuan F, Zhang LS, Li HY, Liao M, Lv M and
Zhang C: Influence of angiotensin I-converting enzyme gene
polymorphism on hepatocellular carcinoma risk in China. DNA Cell
Biol. 32:268–273. 2013. View Article : Google Scholar
|
|
39
|
Patel SP and Kurzrock R: PD-L1 Expression
as a predictive biomarker in cancer immunotherapy. Mol Cancer Ther.
14:847–856. 2015. View Article : Google Scholar
|
|
40
|
Robert C, Ribas A, Wolchok JD, Hodi FS,
Hamid O, Kefford R, Weber JS, Joshua AM, Hwu WJ, Gangadhar TC, et
al: Anti-programmed-death-receptor-1 treatment with pembrolizumab
in ipilimumab-refractory advanced melanoma: A randomised
dose-comparison cohort of a phase 1 trial. Lancet. 384:1109–1117.
2014. View Article : Google Scholar
|
|
41
|
Meng X, Huang Z, Teng F, Xing L and Yu J:
Predictive biomarkers in PD-1/PD-L1 checkpoint blockade
immunotherapy. Cancer Treat Rev. 41:868–876. 2015. View Article : Google Scholar
|
|
42
|
Shen MQ, Sun CY and Liu ZJ: Expression and
clinical significance of B7-H1 and PD-1 in primary hepatocellular
carcinoma tissues. WJCD. 16:3110–3113. 2008.
|
|
43
|
Zeng Z, Shi F and Zhang M: Significance of
PD-1 expression on CD8+ T lymphocytes from patients with
hepatocellular carcinoma. Infect Dis Info. 22:83–85. 2009.
|
|
44
|
Chang H, Jung W, Kim A, Kim HK, Kim WB,
Kim JH and Kim BH: Expression and prognostic significance of
programmed death protein 1 and programmed death ligand-1, and
cytotoxic T lymphocyte-associated molecule-4 in hepatocellular
carcinoma. APMIS. 125:690–698. 2017. View Article : Google Scholar
|
|
45
|
Di Bisceglie AM: Hepatitis B and
hepatocellular carcinoma. Hepatology. 49(Suppl): S56–S60. 2009.
View Article : Google Scholar
|
|
46
|
Evans A, Riva A, Cooksley H, Phillips S,
Puranik S, Nathwani A, Brett S, Chokshi S and Naoumov NV:
Programmed death 1 expression during antiviral treatment of chronic
hepatitis B: Impact of hepatitis B e-antigen seroconversion.
Hepatology. 48:759–769. 2008. View Article : Google Scholar
|
|
47
|
Joseph RW, Cappel M, Goedjen B, Gordon M,
Kirsch B, Gilstrap C, Bagaria S and Jambusaria-Pahlajani A:
Lichenoid dermatitis in three patients with metastatic melanoma
treated with anti-PD-1 therapy. Cancer Immunol Res. 3:18–22. 2015.
View Article : Google Scholar
|
|
48
|
Hamid O, Robert C, Daud A, Hodi FS, Hwu
WJ, Kefford R, Wolchok JD, Hersey P, Joseph RW, Weber JS, et al:
Safety and tumor responses with lambrolizumab (anti-PD-1) in
melanoma. N Engl J Med. 369:134–144. 2013. View Article : Google Scholar
|
|
49
|
Eto S, Yoshikawa K, Nishi M, Higashijima
J, Tokunaga T, Nakao T, Kashihara H, Takasu C, Iwata T and Shimada
M: Programmed cell death protein 1 expression is an independent
prognostic factor in gastric cancer after curative resection.
Gastric Cancer. 19:466–471. 2016. View Article : Google Scholar
|
|
50
|
Hersey P, Ribas A, Hodi FS, Kefford R,
Hamid O, Daud A, Wolchok JD, Hwu WJ, Gangadhar TC, Patnaik A, et
al: Efficacy and safety of the anti-PD-1 monoclonal antibody
MK-3475 in 411 patients (pts) with melanoma. Asia Pac J Clin Oncol.
10:48–49. 2014.
|
|
51
|
Gabrielson A, Wu Y, Kallakury B, Jiang J,
Wang H, Johnson LB, Island E, Fishbein T, Satoskar R, Jha R, et al:
A high density of tumor infiltrating CD3 and CD8 cells to predict
recurrence free survival in patient with hepatocellular carcinoma.
J Clin Oncol. 33(Suppl 3): 2802015. View Article : Google Scholar
|
|
52
|
Curran MA, Montalvo W, Yagita H and
Allison JP: PD-1 and CTLA-4 combination blockade expands
infiltrating T cells and reduces regulatory T and myeloid cells
within B16 melanoma tumors. Proc Natl Acad Sci USA. 107:4275–4280.
2010. View Article : Google Scholar
|
|
53
|
Keir ME, Liang SC, Guleria I, Latchman YE,
Qipo A, Albacker LA, Koulmanda M, Freeman GJ, Sayegh MH and Sharpe
AH: Tissue expression of PD-L1 mediates peripheral T cell
tolerance. J Exp Med. 203:883–895. 2006. View Article : Google Scholar
|
|
54
|
Zeng Z, Shi F, Zhou L, Zhang MN, Chen Y,
Chang XJ, Lu YY, Bai WL, Qu JH, Wang CP, et al: Upregulation of
circulating PD-L1/PD-1 is associated with poor post-cryoablation
prognosis in patients with HBV-related hepatocellular carcinoma.
PLoS One. 6:e236212011. View Article : Google Scholar
|
